542 related articles for article (PubMed ID: 22198049)
1. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.
Macciò A; Madeddu C; Gramignano G; Mulas C; Floris C; Sanna E; Cau MC; Panzone F; Mantovani G
Gynecol Oncol; 2012 Mar; 124(3):417-25. PubMed ID: 22198049
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Madeddu C; Dessì M; Panzone F; Serpe R; Antoni G; Cau MC; Montaldo L; Mela Q; Mura M; Astara G; Tanca FM; Macciò A; Mantovani G
Clin Nutr; 2012 Apr; 31(2):176-82. PubMed ID: 22047681
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Mantovani G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):292-301. PubMed ID: 20496538
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C
Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
Mantovani G; Macciò A; Madeddu C; Serpe R; Massa E; Dessì M; Panzone F; Contu P
Oncologist; 2010; 15(2):200-11. PubMed ID: 20156909
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Wen HS; Li X; Cao YZ; Zhang CC; Yang F; Shi YM; Peng LM
Chemotherapy; 2012; 58(6):461-7. PubMed ID: 23406994
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
Gramignano G; Lusso MR; Madeddu C; Massa E; Serpe R; Deiana L; Lamonica G; Dessì M; Spiga C; Astara G; Macciò A; Mantovani G
Nutrition; 2006 Feb; 22(2):136-45. PubMed ID: 16459226
[TBL] [Abstract][Full Text] [Related]
8. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G; Macciò A; Madeddu C; Gramignano G; Lusso MR; Serpe R; Massa E; Astara G; Deiana L
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1030-4. PubMed ID: 16702388
[TBL] [Abstract][Full Text] [Related]
9. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Cerchietti LC; Navigante AH; Castro MA
Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
[TBL] [Abstract][Full Text] [Related]
10. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
[TBL] [Abstract][Full Text] [Related]
11. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.
Mantovani G; Madeddu C; Macciò A; Gramignano G; Lusso MR; Massa E; Astara G; Serpe R
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1651-9. PubMed ID: 15466983
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.
Bruera E; Ernst S; Hagen N; Spachynski K; Belzile M; Hanson J; Summers N; Brown B; Dulude H; Gallant G
Cancer Prev Control; 1998 Apr; 2(2):74-8. PubMed ID: 9765767
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.
Mantovani G; Maccio A; Madeddu C; Massa E; Mudu MC; Mulas C; Gramignano G; Massidda S; Murgia V; Lusso MR; Mura L
Int J Oncol; 2001 Feb; 18(2):383-91. PubMed ID: 11172608
[TBL] [Abstract][Full Text] [Related]
14. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers.
Kouchaki B; Janbabai G; Alipour A; Ala S; Borhani S; Salehifar E
Support Care Cancer; 2018 Jul; 26(7):2479-2489. PubMed ID: 29442239
[TBL] [Abstract][Full Text] [Related]
16. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
Lai V; George J; Richey L; Kim HJ; Cannon T; Shores C; Couch M
Head Neck; 2008 Jan; 30(1):67-74. PubMed ID: 17615567
[TBL] [Abstract][Full Text] [Related]
17. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome.
Yeh S; Wu SY; Levine DM; Parker TS; Olson JS; Stevens MR; Schuster MW
J Nutr Health Aging; 2000; 4(4):246-51. PubMed ID: 11115810
[TBL] [Abstract][Full Text] [Related]
18. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients.
Fortunati N; Manti R; Birocco N; Pugliese M; Brignardello E; Ciuffreda L; Catalano MG; Aragno M; Boccuzzi G
Oncol Rep; 2007 Dec; 18(6):1521-7. PubMed ID: 17982639
[TBL] [Abstract][Full Text] [Related]
19. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.
Mantovani G; Macciò A; Madeddu C; Serpe R; Antoni G; Massa E; Dessì M; Panzone F
J Mol Med (Berl); 2010 Jan; 88(1):85-92. PubMed ID: 19802504
[TBL] [Abstract][Full Text] [Related]
20. Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression.
Orme LM; Bond JD; Humphrey MS; Zacharin MR; Downie PA; Jamsen KM; Mitchell SL; Robinson JM; Grapsas NA; Ashley DM
Cancer; 2003 Jul; 98(2):397-405. PubMed ID: 12872362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
